Eton Pharmaceuticals, Inc. (ETON) · Nov 5, 2026 · Earnings

Eton earnings beat as revenue surges and guidance jumps

Beat — Non-GAAP diluted EPS $0.50 vs ~$0.31–$0.34 consensus; revenue $57.9M vs ~$42M

Eton’s third-quarter earnings substantially beat published expectations, with 158% revenue growth, 49% adjusted EBITDA margin, and higher 2026 guidance.

Eton is transitioning from a product-acquisition story into a scaled rare-disease commercial platform: HEMANGEOL is now contributing meaningfully, IMPAVIDO launched in September, and the company is building 2027 growth options around ASN-001, LIBERVANT and label expansions. Its prior baseline already included strong momentum, with Q2 revenue up 99% and 2026 guidance recently raised to more than $145 million with at least a 35% adjusted EBITDA margin.

The quarter was materially ahead of the market’s bar. Revenue reached $57.9 million versus published estimates around $42 million, while non-GAAP diluted EPS was $0.50 versus published estimates of roughly $0.31–$0.34. The revenue beat is especially meaningful because it came on top of an already elevated Q2 outlook, not against a weak starting point.

Metric	Q3 2026	Q3 2025	Consensus / prior guide
Revenue (Net Revenue)	$57.9M (+158%)	$22.5M	~$42M consensus
Adjusted EBITDA margin (Financial Highlights)	49%	13%	35% FY guide prior
Non-GAAP diluted EPS (Reconciliation)	$0.50	$0.04	~$0.31–$0.34 consensus
2026 revenue guidance (Guidance)	>$175M	—	>$145M prior
2026 adjusted EBITDA margin (Guidance)	≥40%	—	≥35% prior

The stronger signal is operating leverage, not the headline GAAP profit. Adjusted EBITDA margin expanded to 49% from 13% a year ago and 43% in Q2, while adjusted gross margin reached 80%. That indicates the HEMANGEOL contribution and portfolio growth are scaling faster than the cost base, although G&A nearly doubled as Eton expanded its commercial infrastructure. 〔0〕

Management raised the outlook by more than the quarter alone required. Full-year revenue guidance moved from above $145 million to above $175 million, and the adjusted EBITDA margin floor rose from 35% to 40%. That is a meaningful upgrade to the operating story, not merely a reaffirmation of momentum.

GAAP EPS overstates the quarter’s recurring earnings improvement. GAAP net income included a $12.9 million deferred-tax valuation allowance release; excluding that one-time benefit, non-GAAP net income was $16.5 million, or $0.50 per diluted share. The underlying result still beat expectations decisively, but the tax item should not be treated as ongoing earnings power. 〔1〕

The pipeline adds future optionality, but remains execution-dependent. LIBERVANT has a March 29, 2027 PDUFA date, ASN-001 is expected to enter a bioavailability study in January 2027, and ET-900 is targeting first patient dosing in the first quarter of 2027. Those milestones reinforce the growth platform, but they are future catalysts rather than contributors to this quarter’s beat. 〔2〕

Bottom line: This was a genuine earnings beat with unusually strong margin expansion and a substantial guidance upgrade. It advances Eton’s story from “building a commercial portfolio” toward “scaling a profitable rare-disease platform,” while the tax benefit means the recurring earnings gain is smaller than GAAP EPS suggests.

What to watch next

LIBERVANT FDA decision, March 29, 2027

Original filing on SEC EDGAR

More Eton Pharmaceuticals, Inc. news

Live · an AI on the whole US market

Breaking down Wall Street's information edge.

A buy-side analyst on every ticker.

It reads every public company's filing the second it drops — decoded into plain English, before it's a headline. The edge every investor deserves, not just the desks.

Trade the facts, not the FOMO.

Every event

8-Ks decoded the moment they file

Every number

Fundamentals, valuation, quality

What's next

Earnings calendar + the analyst view

scroll ↓

From filing to your screen in seconds

AllSight is the fastest.

DETECT

The moment it files

Every public company, around the clock. The AI never blinks and never takes lunch — nothing to set up.

filed 9:41:03 · decoded 9:41:19

DECODE

Plain English — never a call.

The event, the numbers, how it sits vs. expectations — in seconds. The AI decodes it; you pull the trigger.

DELIVER

On your screen, before the bell

Overnight and premarket, it's already read everything. You walk into every session with the setup — not scrambling to find it.

Understand it like a Wall Street analyst. Explained like a friend.

the raw filing — read the original on SEC.gov↗

decoded▸

AllSight · BlackBerry Q2 FY27

Revenue $163.3M vs ~$144M expected; adjusted basic EPS $0.07 vs ~$0.04 consensus — a real upside surprise.Income statement
QNX revenue +27% to $80.3M; segment EBITDA $29.0M from $20.5M. “Record performance… core automotive.”Segment — QNX
Licensing jumped to $22.1M from $6.6M — it amplified the beat, but it's less recurring than QNX, so the quality sits in QNX.Segment — Licensing
FY27 guide lifted to $616–636M rev / $141–158M EBITDA, above the prior $594–621M / $119–139M framework.Guidance
QNX growth, margins, cash and a raised outlook all beat. But licensing amplified it and Secure Comms is flat — net retention 91% from 93%.Segment — Secure Comms

Know a company all the way down.

Not just one filing. AllSight profiles every public company end to end — the numbers, the quality, the insiders, the smart money, the Street. One page, nothing missed.

Price & every insider trade, plotted
A quality score ranked against every peer
40+ valuation & profitability multiples
Where each one sits in its 5-year range
Whole-market insider flow, in real time
Which superinvestors are holding it
Analyst consensus & price target

Live · — filings read this week

AllSight gives you an edge others can't.

One scan before the open, one after the close — every filing on every ticker, already decoded. You walk into every session fully prepared.

Not investment advice · a neutral translation you can check against the original SEC filing

allsight.ai

Events/ANDE/8-K · Earnings

8-K · Item 2.02 · Earnings

The Andersons — a record Renewables quarter that beat profit expectations

Filed Aug 3, 2026ANDE · NASDAQ

AllSight readBeatPriced in▲ 1.8% since filed · reaction agrees

adj. EPS $2.15 vs ~$1.48 consensus

This filing tests whether The Andersons' sharp profit increase reflects broad operating improvement or a one-off renewable-fuels boost. It also separates strong adjusted earnings and cash generation from the quarter's legal and impairment charges.

The quarter was substantially stronger than both last year and the published earnings expectation. Adjusted EPS reached $2.15, versus $0.24 a year earlier and above the published consensus of about $1.48; reported EPS was $1.65. Adjusted EBITDA more than doubled to $140 million, while sales slipped modestly — the improvement came from margins and operating performance rather than higher revenue. Financial Highlights · Statements of Operations

Q2 ($M, exc. per-share)	Q2 2026	Q2 2025	YoY
Sales & merchandising revenue	3,097.7	3,135.9	−1%
Net income (attributable)	56.6	7.9	+48.7
Diluted EPS	1.65	0.23	+1.42
Adjusted EPS	2.15	0.24	+1.91
Adjusted EBITDA	140.3	65.2	+75.1
Agribusiness adj. pretax	20.3	16.8	+3.5
Renewables adj. pretax	88.4	9.6	+78.8
Cash from operations	487.9	299.3	+188.6
Cash from ops (pre-WC)	112.9	42.9	+70.1

Renewables drove nearly all of the upside — the operating backdrop was strong, but the result also benefited materially from tax credits. Renewables' adjusted pretax income rose to $88 million on record production, stronger ethanol margins and merchandising gains. It also received $24 million of 45Z producer tax credits, so this was not solely a repeatable plant-margin improvement; the company did cite healthy export and domestic ethanol demand as supportive. Renewables — Record Q2 · Segment Data

Agribusiness improved, but it was a supporting contributor rather than the main earnings engine. Adjusted pretax income increased to $20 million as fertilizer margins improved and merchandising benefited from commodity-price volatility, despite lower fertilizer volumes. Agribusiness — Improved Q2 · Segment Data

Cash generation improved and funding capacity is comfortable, while reported earnings still absorbed meaningful non-core costs. Operating cash flow was $488 million ($113 million before working-capital changes); capital spending was $76 million. Adjusted EPS excludes $0.50 of legal-settlement, impairment and transaction items, so the $2.15 adjusted result runs ahead of the $1.65 reported. Leverage stays below the <2.5× debt-to-EBITDA target; no new quantified full-year outlook was given. Cash & Liquidity · Adjusted Net Income

Community sentiment · 612 votes

58% bullish

Bull 58%Neu 27%Bear 15%

AllSight

AllSight Pro

A buy-side analyst on every ticker — reading the whole market the second it moves.

It reads every public company's filing the instant it drops and hands you what it means — in plain English, before it's a headline.

The read itself

Not another feed. A buy-side analyst that never sleeps, on everything.

Whole-market breadthevery public company

Not the 20 names CNBC repeats. Every ticker that files — thousands of companies, one AI reading all of them.

Filed-to-decoded in secondsspeed

Filed 9:41:03, decoded 9:41:19. You've got the catalyst while the tape is still moving and the crowd's still on the headline.

Past the headlinedepth

What actually happened, the numbers that matter, how it sits vs what the Street expected, and what it sets up next.

Source-grounded & neutralrigor

Every read traces to the words in the actual filing — click to see them. A translation you can check, never a buy/sell call.

Zero effort to youconvenience

Plain English, one glance. Follow your stocks and the moment any of them files, it's in your pocket — no watching, no digging.

All of it, livePro

Free reads every session once it closes. Pro reads it the moment it files: the whole market, all day, every day.

And then — go deeper

From "what happened" to "is it worth it."

Cheap or dear?Where it trades vs its own valuation history.

The quality score, in fullAll five dimensions, ranked against its sector.

Structure & multi-year trendsRevenue, margins, cash — the hard numbers, decoded.

Insider activityWho inside the company is buying and selling.

Analyst price targetsWhere Wall Street says every name is headed.

The whole company, one pagePrice, ownership, the full read — on any ticker.

Hire your personal buy-side analyst.

Trade one usual slippage for a whole market's rhythm.

Free

forever

Every closed session, on the whole market. The live session and the deep company read stay Pro.

Monthly

$29/mo

billed monthly

Everything, live — every session the moment it files, plus the full company read. Flexible, month to month.

Best value · save 40%

Annual

$17.40/mo

$209 billed yearly

about one slippage a month

Same full access — the whole market live and every company — at the lowest price. 40% off the monthly.

Billed today. Powered by Stripe · AllSight never sees your card.

Eton earnings beat as revenue surges and guidance jumps

What to watch next

More Eton Pharmaceuticals, Inc. news

Breaking down Wall Street's information edge.